Retinal Vein Occlusion: Beyond the Acute Event

• Published in: Survey of ophthalmology Vol. 56; no. 4; pp. 281 - 299
• Main Authors: Ehlers, Justis P., MD, Fekrat, Sharon, MD
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01-07-2011; Elsevier
• Subjects: Angiogenesis Inhibitors - therapeutic use; arteriovenous sheathotomy; bevacizumab; Biological and medical sciences; branch retinal vein occlusion (BRVO); central retinal vein occlusion (CRVO); cystoid macular edema (CME); hemiretinal vein occlusion (HRVO); Humans; macular edema; Medical sciences; Miscellaneous; Ophthalmologic Surgical Procedures; Ophthalmology; radial optic neurotomy; ranibizumab; Retinal vein occlusion; Retinal Vein Occlusion - diagnosis; Retinal Vein Occlusion - etiology; Retinal Vein Occlusion - therapy; Retinopathies; triamcinolone; vascular endothelial growth factor (VEGF); Retinal vein occlusion; cystoid macular edema (CME); hemiretinal vein occlusion (HRVO); bevacizumab; branch retinal vein occlusion (BRVO); vascular endothelial growth factor (VEGF); macular edema; triamcinolone; central retinal vein occlusion (CRVO); ranibizumab; arteriovenous sheathotomy; radial optic neurotomy; Antineoplastic agent; Occlusion; Retinopathy; Cystoid macular edema; Cardiovascular disease; Maculopathy; Monoclonal antibody; Venous disease; Bevacizumab; Vascular disease; radial optic neurotomy triamcinolone; Branch; Ranibizumab; Ophthalmology; Antiangiogenic agent; Vein; Corticosteroid; Acute; Antiinflammatory agent; Radial optic neurotomy; Retinal edema; hemiretinal; Immunomodulator; Central retinal vein occlusion; vein occlusion (HRVO); Eye disease; Vascular endothelium growth factor; Adrenal hormone; Triamcinolone
• ISSN: 0039-6257; 1879-3304
• DOI: 10.1016/j.survophthal.2010.11.006

Abstract Retinal vein occlusion is a major cause of vision loss. We provide an overview of the clinical features, pathogenesis, natural history, and management of both branch retinal vein occlusion and central retinal vein occlusion. Several recent multicenter randomized clinical trials have been completed which have changed the approach to this disorder. Management of retinal vein occlusions can be directed at the underlying etiology or the resulting sequelae. Options include surgical intervention, laser photocoagulation, intravitreal pharmacotherapy, and sustained drug delivery devices.